BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro

Reuters12-12

BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro

** Shares of telehealth firm Hims & Hers Health HIMS.N fall 3.5% to $29.82

** Private telehealth co Ro says it will offer single-dose vials of Eli Lilly's LLY.N weight-loss drug, Zepbound, to patients with obesity

** Ro becomes the first alternative platform for lower-cost version of the drug to Lilly's own website

** "Ro being first may result in HIMS being boxed out from the DTC Zepbound channel," Leerink Partners says

** Brokerage adds, "on the other hand, this data point could be seen as a positive for HIMS, as it shows that HIMS could also pursue a similar strategy working with a manufacturer like Lilly"

** In August, Lilly started selling vials of lowest starter dose of Zepbound in the United States through its direct-to-consumer website LillyDirect

** The vials are available for the same price through Ro, the telehealth firm said

** Including session's moves, HIMS shares more than tripled YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490389551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490389551","market":"us","top_or_hot":-1,"title":"BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro </title></head><body><p> ** Shares of telehealth firm Hims &amp; Hers Health <span>HIMS.N</span> fall 3.5% to $29.82  </p><p>** Private telehealth co Ro <span>says</span> it will offer single-dose vials of Eli Lilly's <span>LLY.N</span> weight-loss drug, Zepbound, to patients with obesity</p><p>** Ro becomes the first alternative platform for lower-cost version of the drug to Lilly's own website</p><p>** \"Ro being first may result in HIMS being boxed out from the DTC Zepbound channel,\" Leerink Partners says</p><p>** Brokerage adds, \"on the other hand, this data point could be seen as a positive for HIMS, as it shows that HIMS could also pursue a similar strategy working with a manufacturer like Lilly\" </p><p>** In August, Lilly started selling vials of lowest starter dose of Zepbound in the United States through its direct-to-consumer website LillyDirect</p><p>** The vials are available for the same price through Ro, the telehealth firm said</p><p>** Including session's moves, HIMS shares more than tripled YTD</p><p> (Reporting by Sneha  S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 01:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC1ET:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro  ** Shares of telehealth firm Hims & Hers Health HIMS.N fall 3.5% to $29.82  ** Private telehealth co ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC1ET:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC1ET:1","article_id":"2490389551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490389551","pubTimestamp":1733939901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro  ** Shares of telehealth firm Hims & Hers Health HIMS.N fall 3.5% to $29.82  ** Private telehealth co Ro says it will offer single-dose vials of Eli Lilly's LLY.N weight-loss drug, Zepbound, to patients with obesity** Ro becomes the first alternative platform for lower-cost version of the drug to Lilly's own website** \"Ro being first may result in HIMS being boxed out from the DTC Zepbound channel,\" Leerink Partners says** Brokerage adds, \"on the other hand, this data point could be seen as a positive for HIMS, as it shows that HIMS could also pursue a similar strategy working with a manufacturer like Lilly\" ** In August, Lilly started selling vials of lowest starter dose of Zepbound in the United States through its direct-to-consumer website LillyDirect** The vials are available for the same price through Ro, the telehealth firm said** Including session's moves, HIMS shares more than tripl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc."},"translate_title":"BUZZ-Hims&Hers紧随礼来公司在远程医疗平台Ro上提供单剂量Zepbound小瓶之后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"BUZZ-Hims & Hers falls after Lilly to offer single-dose Zepbound vials on telehealth platform Ro  ** Shares of telehealth firm Hims & Hers Health HIMS.N fall 3.5% to $29.82  ** Private telehealth co Ro says it will offer single-dose vials of Eli Lilly's LLY.N weight-loss drug, Zepbound, to patients with obesity** Ro becomes the first alternative platform for lower-cost version of the drug to Lilly's own website** \"Ro being first may result in HIMS being boxed out from the DTC Zepbound channel,\" Leerink Partners says** Brokerage adds, \"on the other hand, this data point could be seen as a positive for HIMS, as it shows that HIMS could also pursue a similar strategy working with a manufacturer like Lilly\" ** In August, Lilly started selling vials of lowest starter dose of Zepbound in the United States through its direct-to-consumer website LillyDirect** The vials are available for the same price through Ro, the telehealth firm said** Including session's moves, HIMS shares more than tripled YTD (Reporting by Sneha  S K) ((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490389551"}